KGK Science Inc. Expands Capabilities with Growth Investment from Maxim Partners
LONDON, ON and CHICAGO, July 27, 2026 /PRNewswire/ — KGK Science Inc., a prominent North American contract research organization focused on clinical trials and regulatory services in the dietary supplement and consumer health sectors, has secured a significant growth investment led by Maxim Partners. This investment supports KGK’s ambition to enhance its clinical research and regulatory capabilities.
Founded in 1997, KGK has successfully completed over 400 clinical trials spanning more than 40 health conditions and has published over 150 peer-reviewed articles. The organization specializes in providing clinical research, regulatory consulting, and claim substantiation services, aiding consumer health companies in developing scientifically validated products.
The investment will bolster KGK’s clinical trial capacity, promote decentralized and virtual trial initiatives, expand regulatory services, and grow its commercial organization. The company will continue to be led by Founder and CEO Najla Guthrie and the current management team.
Najla Guthrie commented, “This investment marks an exciting new chapter for our company. Maxim Partners shares our long-term vision and brings the necessary strategic resources to help us grow and better serve our clients.”
Gregg Wilson, Founder & Managing Partner of Maxim Partners, highlighted KGK’s strong reputation for scientific rigor and customer service, expressing confidence in the company’s potential to capitalize on increasing demand for clinically validated nutrition products.
About KGK Science
KGK Science, based in London, Ontario, specializes in conducting human clinical trials and providing regulatory expertise for the nutraceutical sector. For more information, visit kgkscience.com.
About Maxim Partners
Maxim Partners is a Chicago-based investment firm focused on supporting innovative ventures in nutrition and healthcare. For further details, visit maximpartnersllc.com.
For the original press release and multimedia, visit PR Newswire.
SOURCE: Maxim Partners
